Trial reportJournal of neuroengineering and rehabilitation2025
Effect of upper-limb robot-assisted therapy combined with pneumatic gloves on upper limb function in young and middle-aged stroke patients: a pilot randomized controlled trial.
Trial report in Journal of neuroengineering and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotrophin System as a Complex Set of Potential Biomarkers in Psychiatric Disorders and Therapy-Overview of Recent Advances.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the effects of an end-effector-type upper-limb robot-assisted therapy (UL-RAT) combined with pneumatic gloves (PGs) on improving upper limb function in young and middle-aged stroke patients.
methodsForty young and middle-aged stroke patients were recruited and randomized into two groups, including a UL-RAT&PG group and a control group, with 20 cases in each group. The control group received conventional upper limb occupational therapy once a day, 5 days a week, for a total of 4 weeks. The UL-RAT&PG group received the combination of UL-RAT and PGs once a day, 5 days a week, for a total of 4 weeks. To evaluate their upper limb function, the primary assessment indices were the Fugl-Meyer assessment extremities (FMA-UE) and Action Research Arm Test (ARAT), and the secondary assessment indices included the Canadian Occupational Performance Measure (COPM), modified Ashworth Scale (MAS), National Institutes of Health Stroke Scale (NIHSS), and modified Barthel index (MBI). To assess brain plasticity, Quantitative electroencephalogram (qEEG) and diffusion tensor imaging (DTI) were performed. Additionally, Enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay were conducted to evaluate serum brain-derived neurotrophic factor (BDNF) and microRNA-132 (miRNA-132) levels. Finally, the Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and Exercise Adherence Questionnaire Scale (EAQ) were used to assess patients' emotional states and compliance with the therapy.
resultsAfter treatment, both groups showed significantly greater improvements in upper limb function. The FMA-UE, ARAT, COPM-executive ability, COPM-satisfaction, and MBI scores of the UL-RAT&PG group were 52.30 ± 1.94, 47.65 ± 7.41, 4.61 ± 1.86, 5.92 ± 1.65, and 87.10 ± 11.11, that all considerably higher than those of the control group (38.6 ± 16.97, 29.90 ± 15.39, 3.39 ± 1.66, 3.61 ± 1.67, and 69.95 ± 17.62), and their NIHSS scores were 1.75 ± 1.12, significantly lower than those of the control group (3.70 ± 1.63). DTABR scores and corticospinal tract (CST) morphology showed positive changes in both groups, indicating an improvement in brain plasticity. The serum BDNF and miRNA-132 levels of both groups were markedly higher than before treatment. In addition, SAS and SDS scores of the control group were 34.55 ± 8.48 and 45.25 ± 12.01, and = UL-RAT&PG groups were 37.85 ± 5.72 and 38.70 ± 8.99, all significantly lower than those before treatment (37.85 ± 9.92 and 49.95 ± 12.59, 42.95 ± 7.62 and 46.10 ± 11.29), indicating that their negative emotions have alleviated. However, the above results of serum BDNF, miRNA-132, SAS, and SDS had no statistical difference between the two groups. Notably, compared to the control group (49.95 ± 12.59), patients in the UL-RAT&PG group had a higher EAQ score (46.10 ± 11.29), indicating better exercise compliance.
conclusionsThe combination of the UL-RAT and PGs can significantly improve upper limb function, compliance, serum BDNF, and serum miRNA-132, and attenuate depression and anxiety in young and middle-aged stroke patients. Trial registration The study was registered on the Chinese Clinical Trial Registry (ChiCTR2500097887).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.